IncobotulinumtoxinA (Xeomin)

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: the treatment or improvement of: chronic sialorrhea in patients 2 years of age and older (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Parkinson's Disease · Phase 3

Also approved (1)
US
  • XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: chronic sialorrhea in patients 2 years of age and older; Upper limb spasticity in patients 2 years of age and older; Cervical dystonia in adults; Blepharospasm in adults; the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity; moderate to severe horizontal forehead lines associated with frontalis muscle activity; moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity.
Product first approved 2010Outside this platform's coverageFDA label

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (23)
Migraine
NCT05598723 · Naval Medical Center Camp Lejeune
2023-02-24 – 2027-08-24 · Chronic Migraine
What this study did
Parkinson's Disease
NCT02091739 · Merz Pharmaceuticals GmbH
2014-04 – 2016-11 · Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
What this study did
Other / comorbidity
NCT06995287 · Nantes University Hospital
2026-02-09 – 2028-09-09 · Primary Dysmenorrhea, Chronic Pelvic Pain
What this study did
NCT03977493 · Alain Kaelin
2018-02-21 – 2027-12-31 · Focal Hand Dystonia
What this study did
NCT04075981 · Assistance Publique - Hôpitaux de Paris
2019-09-30 – 2026-09-22 · Cardiac Surgery
What this study did
NCT05980559 · Alexandria University
2024-01-15 – 2024-04-15 · Bruxism
What this study did
NCT03758235 · University Of Perugia
2018-09-01 – 2021-09-01 · Overactive Bladder Syndrome
What this study did
NCT01896895 · Merz Pharmaceuticals GmbH
2013-11 – 2016-11 · Bilateral Blepharospasm (BEB)
What this study did
NCT01098019 · Innovaderm Research Inc.
2010-04 – 2012-02 · Notalgia Paresthetica
What this study did
NCT00512135 · Merz Pharmaceuticals GmbH
2007-06-18 – 2009-12-28 · Glabellar Lines
What this study did
NCT00406367 · Merz Pharmaceuticals GmbH
2006-10 – 2009-07 · Blepharospasm
What this study did
NCT00770211 · Merz Pharmaceuticals GmbH
2008-10 – 2009-06 · Moderate to Severe Glabellar Frown Lines
What this study did
NCT00770029 · Merz Pharmaceuticals GmbH
2008-10 – 2009-06 · Moderate to Severe Glabellar Frown Lines
What this study did
NCT00407030 · Merz Pharmaceuticals GmbH
2006-07 – 2009-06 · Cervical Dystonia
What this study did
NCT00777803 · Merz Pharmaceuticals GmbH
2008-11 – 2009-05 · Glabellar Frown Lines
What this study did
NCT00432666 · Merz Pharmaceuticals GmbH
2006-06 – 2008-05 · Post-stroke Upper Limb Spasticity
What this study did
NCT00465738 · Merz Pharmaceuticals GmbH
2007-02 – 2008-05 · Upper Limb Spasticity
What this study did
NCT00541723 · Merz Pharmaceuticals GmbH
2007-09 – 2008-05 · Lateral Periorbital Wrinkles
What this study did
NCT00430963 · Merz Pharmaceuticals GmbH
2006-10 – 2007-11 · Glabellar Frown Lines
What this study did
Phase 2 (13)
Parkinson's Disease
NCT01653132 · Beth Israel Deaconess Medical Center
2012-03 – 2014-09 · Sialorrhea
What this study did
Other / comorbidity
NCT07537855 · Northwestern University
2026-09 – 2028-09 · Erectile Dysfunction
What this study did
NCT05327972 · Assistance Publique - Hôpitaux de Paris
2023-01-20 – 2027-02 · Degenerative Rotator Cuff Disease
What this study did
NCT05340439 · Universita di Verona
2022-06 – 2025-05 · Spastic Cerebral Palsy
What this study did
NCT03571334 · Medical College of Wisconsin
2020-07-08 – 2024-12-31 · Peripheral Neuropathy Due to Chemotherapy
What this study did
NCT06034288 · Walter Reed National Military Medical Center
2023-05-04 – 2024-09-30 · Overactive Bladder Syndrome
What this study did
NCT02107261 · Icahn School of Medicine at Mount Sinai
2014-03 – 2020-01-27 · Dystonia
What this study did
NCT03119948 · Assistance Publique - Hôpitaux de Paris
2014-12 – 2018-12 · Hemiparesis After Stroke, Traumatic Brain Injury
What this study did
NCT02188277 · Merz Pharmaceuticals GmbH
2014-07 – 2016-12 · Cerebral Palsy, Spastic Paraplegia and Hemiparesis, Equine and Equinovarus Foot Deformation
What this study did
NCT02207946 · Merz Pharmaceuticals GmbH
2014-12-05 – 2016-09-26 · Essential Tremor of the Upper Limbs
What this study did
NCT01931878 · Yale University
2012-09 – 2015-08 · Restless Leg Syndrome
What this study did
Phase 1 (3)
Other / comorbidity
NCT05305768 · Clinical Testing of Beverly Hills
2022-05-01 – 2023-02 · Glabellar Frown Lines
What this study did
NCT00515944 · Merz Pharmaceuticals GmbH
2007-08 – 2008-06 · Healthy
What this study did
Phase 4 (9)
Other / comorbidity
NCT04908423 · Wake Forest University Health Sciences
2021-10-19 – 2028-04 · Stroke
What this study did
NCT04792398 · Dominik Ettlin
2021-05-01 – 2023-06 · Sleep Bruxism, Adult
What this study did
NCT05039723 · Main Line Center for Laser Surgery
2021-09-01 – 2022-07-01 · Photoaging
What this study did
NCT03376464 · Erevna Innovations Inc.
2015-11-06 – 2017-10-11 · Masseter Muscle Hypertrophy
What this study did
NCT01968902 · Multiple Sclerosis Center of Northeastern New York
2013-11 – 2016-12-31 · Muscle Spasticity, Multiple Sclerosis
What this study did
NCT01678001 · Rothman Institute Orthopaedics
2012-08 – 2016-08 · Plantar Fascitis
What this study did
NCT01486264 · Merz Pharmaceuticals GmbH
2012-01-20 – 2016-03-29 · Cervical Dystonia
What this study did
NCT01583478 · The Maas Clinic
2014-09 – 2015-12 · Skin Aging, Elastosis Senilis
What this study did
NCT01728337 · Hexsel Dermatology Clinic
2011-07 – 2012-02 · Sun-induced Wrinkles
What this study did
Early phase / not applicable (5)
Other / comorbidity
NCT04544280 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2018-09-13 – 2021-12-31 · Stroke
What this study did
NCT05027243 · Instituto Portugues da Face
2016-01-02 – 2021-07-31 · Bilateral Temporomandibular Joint Disorder
What this study did
NCT04102670 · Nashville Centre for Laser and Facial Surgery
2019-10-01 – 2020-12-01 · Laxity; Skin
What this study did
NCT03129087 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2017-05-23 – 2019-05-01 · Adductor Spasmodic Dysphonia
What this study did
NCT02122536 · YMD Eye and Face
2012-07 – 2013-11 · Facial Wrinkles
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Other / comorbidity
NCT06205797 · Huons Biopharma
2024-06-20 – 2025-03-31 · Glabellar Lines
What this study did
NCT05623410 · ATGC Co., Ltd.
2022-10-11 – 2023-06-10 · Glabellar Frown Lines
What this study did
Phase 2 (1)
Other / comorbidity
NCT05298449 · Huons Co., Ltd.
2022-03-28 – 2023-04-25 · Glabellar Lines
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

This drug's own stage for Migraine: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IncobotulinumtoxinA (Xeomin): this drugPhase 3Protein / enzyme therapeuticacetylcholine releasenot yet gradedNo reviewed efficacy summary in this indication
Aspirin / Acetaminophen / Caffeine (Excedrin Migraine)Approved—Nonsteroidal Anti-inflammatory Drug, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Atogepant (Qulipta)ApprovedSmall moleculeCGRP receptorReliable signal
NCT03777059: Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206)
NCT02848326: Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33)
Celecoxib (Elyxyb)ApprovedSmall moleculeCOX-2Partial signalNo reviewed efficacy summary in this indication
Diclofenac Potassium (Cambia)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine (Atzumi)ApprovedSmall molecule5-HT1D receptorPartial signal
NCT04940390: Co-primary endpoints at 2 hours, STS101 5.2 mg (n=716) vs placebo (n=708), mITT: freedom from pain 146/716 (20.4%) vs 124/708 (17.5%); freedom from most bothersome symptom 265/716 (37.0%) vs 230/708 (32.5%). The sponsor states the differences did not reach statistical significance; no p-values are reported. missed
NCT03901482: Co-primary endpoints at 2 hours, STS101 3.9 mg (n=354) and 5.2 mg (n=353) vs placebo (n=358), mITT: freedom from pain 69/354 (19.5%) and 68/353 (19.3%) vs 53/358 (14.8%); freedom from most bothersome symptom 133/354 (37.6%) and 139/353 (39.4%) vs 119/358 (33.2%). The sponsor states neither dose was statistically significant on either co-primary endpoint; no p-values are reported. missed
Dihydroergotamine Mesylate (Brekiya)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (D.H.E. 45)
ApprovedUS marketing discontinued
Small molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate (Migranal)ApprovedSmall molecule5-HT1D receptornot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eletriptan (Relpax)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Eptinezumab (Vyepti)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT02974153: Change From Baseline in Monthly Migraine Days (Week 1-12): 300 mg ALD403 -8.2 Migraine Days (range -23 to 11) | 100 mg ALD403 -7.7 Migraine Days (range -22 to 10) | Placebo -5.6 Migraine Days (range -25 to 9)
NCT02559895: Change From Baseline in Monthly Migraine Days (Weeks 1-12) (Week 1-12): 300 mg ALD403 -4.3 Migraine Days (Standard Deviation 3.42) | 100 mg ALD403 -3.9 Migraine Days (Standard Deviation 3.23) | 30 mg ALD403 -4.1 Migraine Days (Standard Deviation 3.22) | Placebo -3.1 Migraine Days (Standard Deviation 3.7)
Erenumab (Aimovig)ApprovedMonoclonal antibodyCGRP receptorReliable signal
NCT03867201: Change From Baseline in Monthly Migraine Days During the Last 4 Weeks of the 12-week Treatment Period (baseline (4 weeks period prior to start of study drug), week 9 to 12): Erenumab 70 mg -8.19 days (Standard Error 0.46) | Placebo -6.62 days (Standard Error 0.45)
NCT02456740: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period (4-week baseline phase and the last 3 months (months 4, 5, and 6) of the 24-week double-blind treatment phase): Placebo -1.83 migraine days / month (Standard Error 0.18) | Erenumab 70 mg QM -3.23 migraine days / month (Standard Error 0.18) | Erenumab 140 mg QM -3.67 migraine days / month (Standard Error 0.18)
Ergotamine / Caffeine (Cafergot)
ApprovedUS marketing discontinued
Small moleculeAlpha-adrenergic receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Fremanezumab (Ajovy)ApprovedMonoclonal antibodyCGRP ligandPartial signal
NCT04458857: Change in monthly migraine days over 12 weeks: fremanezumab -2.5 vs placebo -1.4; LS mean difference -1.0 (95% CI -1.90 to -0.16), p=0.0210 (n=123 and 111) (CT.gov posted results).
NCT02621931: Change in monthly headache days of at least moderate severity over 12 weeks (median): fremanezumab 675 mg quarterly -4.2 (n=375) and 675/225/225 mg monthly -4.5 (n=375) vs placebo -2.5 (n=371); LS mean difference from placebo -1.8 (95% CI -2.46 to -1.15) and -2.1 (95% CI -2.76 to -1.45), both p < 0.0001 (Wilcoxon) (CT.gov posted results).
Frovatriptan (Frova)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Galcanezumab (Emgality)ApprovedMonoclonal antibodyCGRP ligandReliable signal
NCT03963232: Change in monthly migraine headache days over 3 months, LS mean -3.81 (galcanezumab 120 mg) vs -1.99 (placebo); difference -1.82 days (95% CI -2.32 to -1.32), p<.0001.
NCT03559257: Change in monthly migraine headache days over months 1 to 3 (treatment-resistant migraine), LS mean -4.14 (galcanezumab 120 mg) vs -1.02 (placebo); difference -3.12 days (95% CI -3.92 to -2.32), p<0.0001.
Ibuprofen (Advil Migraine)ApprovedSmall moleculeNonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Meloxicam / Rizatriptan (Symbravo)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugReliable signalFeatured results are safety only in this race
Naratriptan (Amerge)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
onabotulinumtoxinA (Botox)ApprovedBiologic (subtype unspecified)Acetylcholine Release Inhibitor, acetylcholine releasenot yet gradedNo reviewed efficacy summary in this indication
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Rimegepant (Nurtec ODT)ApprovedSmall moleculeCGRP receptorReliable signal
NCT05810038: Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14)
NCT05399485: Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91)
Rizatriptan (Maxalt)ApprovedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy only in this race
Rizatriptan (RizaFilm)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Onzetra Xsail)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan (Tosymra)ApprovedSmall molecule5-HT1B/1D receptorWeak signalFeatured results are safety only in this race
Sumatriptan Succinate (Sumavel DosePro)
ApprovedUS marketing discontinued
Small molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zembrace SymTouch)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Injection (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Nasal Spray (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate Tablets (Imitrex)ApprovedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan / Naproxen Sodium (Treximet)ApprovedSmall molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory DrugWeak signalNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00236509: Primary endpoint, change in mean 4-week migraine frequency (baseline to double-blind phase, ITT n=469): -1.3, -2.1 and -2.2 with topiramate 50, 100 and 200 mg/day vs -0.8 with placebo; 100 and 200 mg/day vs placebo p<0.001 (TOPAMAX label, Study 11 = TOPMAT-MIGR-001).
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Ubrogepant (Ubrelvy)ApprovedSmall moleculeCGRP receptorReliable signal
NCT04492020: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants
Zavegepant (Zavzpret)ApprovedSmall moleculeCGRP receptorReliable signalNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig Nasal Spray)ApprovedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication
Almotriptan (Axert)US approval withdrawnSmall molecule5-HT1B/1D receptorWeak signalNo reviewed efficacy summary in this indication
ElismetrepPhase 3—TRPM8not yet gradedNo reviewed efficacy summary in this indication
Rizatriptan / NaproxenPhase 3Small molecule5-HT1B/1D receptor, Nonsteroidal Anti-inflammatory Drugnot yet gradedNo reviewed efficacy summary in this indication
Naltrexone / Acetaminophen (ALLOD-2)Phase 2/3—Opioid receptornot yet gradedNo reviewed efficacy summary in this indication
BHV-2100Phase 2—TRPM3not yet gradedNo reviewed efficacy summary in this indication
EVO756Phase 2Small moleculeMRGPRX2not yet gradedNo reviewed efficacy summary in this indication
ABBV-2002
—(overall)
UndisclosedPAR-2not yet gradedNo reviewed efficacy summary in this indication
Dihydroergotamine Mesylate / Dipyrone / Caffeine (Cefaliv)
—(overall)
—5-HT1D receptor, Adenosine receptornot yet gradedNo reviewed efficacy summary in this indication
Dipyrone / Isometheptene Mucate / Caffeine (Neosaldina)
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Lasmiditan (Reyvow)DiscontinuedSmall molecule5-HT1F receptorReliable signalNo reviewed efficacy summary in this indication
Propranolol (Inderal)DiscontinuedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
Sumatriptan Succinate (Zecuity)DiscontinuedSmall molecule5-HT1B/1D receptorPartial signalFeatured results are non-efficacy and safety only in this race
Sumatriptan Succinate Auto-Injector (Alsuma)DiscontinuedSmall molecule5-HT1B/1D receptornot yet gradedNo reviewed efficacy summary in this indication
Zolmitriptan (Zomig)DiscontinuedSmall molecule5-HT1B/1D receptorsnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(8 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IncobotulinumtoxinA (Xeomin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
February 2027 (2)
Phase 2Degenerative Rotator Cuff DiseaseRecruiting
Est. primary completion 2027-02 · NCT05327972 · CT.gov ↗
What to watch
Phase 3MigraineRecruiting
Est. primary completion 2027-02-24 · NCT05598723 · CT.gov ↗
What to watch
March 2027 (2)
Phase 3MigraineActive not recruiting
Est. primary completion 2027-03 · NCT07018713 · CT.gov ↗
What to watch
Phase 3MigraineActive not recruiting
Est. primary completion 2027-03 · NCT07018700 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Focal Hand DystoniaRecruiting
Est. primary completion 2027-12-31 · NCT03977493 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Phase 4StrokeRecruiting
Est. primary completion 2028-04 · NCT04908423 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Primary Dysmenorrhea, Chronic Pelvic PainRecruiting
Est. primary completion 2028-06-09 · NCT06995287 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Erectile DysfunctionNot yet recruiting
Est. primary completion 2028-09 · NCT07537855 · CT.gov ↗
What to watch

See the full readout calendar ↗